Abstract：
UNASSIGNED: Focal epilepsy constitutes the most common epilepsy in children, and medical treatment represents the first-line therapy in this condition. The main goal of medical treatment for children and adolescents with epilepsy is the achievement of seizure freedom or, in drug-resistant epilepsies, a significant seizure reduction, both minimizing antiseizure medications (ASM)-related adverse events, thus improving the patient\'s quality of life. However, up to 20-40% of pediatric epilepsies are refractory to drug treatments. New ASMs came to light in the pediatric landscape, improving the drug profile compared to that of the preexisting ones. Clinicians should consider several factors during the drug choice process, including patient and medication-specific characteristics.
UNASSIGNED: This narrative review aims to summarize the latest evidence on the effectiveness and tolerability of the newest ASMs administered as monotherapy or adjunctive therapy in pediatric epilepsies with focal onset seizures, providing a practical appraisal based on the existing evidence.
UNASSIGNED: The latest ASMs have the potential to be effective in the pharmacological management of focal onset seizures in children, and treatment choice should consider several drug- and epilepsy-related factors. Future treatments should be increasingly personalized and targeted on patient-specific pathways. Future research should focus on discovering new chemical compounds and repurposing medications used for other indications.
UNASSIGNED: This narrative review aims to summarize the latest evidence on the effectiveness and tolerability of the newest ASMs administered as monotherapy or adjunctive therapy in pediatric epilepsies with focal onset seizures, providing a practical appraisal based on the existing evidence.
UNASSIGNED: The latest ASMs have the potential to be effective in the pharmacological management of focal onset seizures in children, and treatment choice should consider several drug- and epilepsy-related factors. Future treatments should be increasingly personalized and targeted on patient-specific pathways. Future research should focus on discovering new chemical compounds and repurposing medications used for other indications.
摘要：
■局灶性癫痫是儿童中最常见的癫痫，在这种情况下，药物治疗是一线选择。治疗儿童和青少年癫痫的主要目标是实现癫痫发作的自由，在耐药性癫痫中，显著减少癫痫发作，既尽量减少抗癫痫药物（ASM）相关的不良事件，从而提高患者的生活质量。然而,高达20-40%的小儿癫痫难以药物治疗。在这方面,新的ASM在儿科领域被发现，与先前存在的药物相比，试图改善药物状况。临床医生在药物选择过程中应考虑几个因素,包括患者和药物的具体特征。
■这篇叙述性综述旨在总结最新的ASM作为单一疗法或辅助疗法用于局灶性发作的小儿癫痫的有效性和耐受性的最新证据。在现有证据的基础上提供实用的评估。
■最新的ASM有可能有效治疗儿童局灶性发作性癫痫，治疗选择应考虑几个药物和癫痫相关因素。未来的治疗应该越来越个性化，并针对患者特定的途径。未来的研究不仅应该专注于发现新的化合物，而且应该专注于重新利用用于其他适应症的药物。
■这篇叙述性综述旨在总结最新的ASM作为单一疗法或辅助疗法用于局灶性发作的小儿癫痫的有效性和耐受性的最新证据。在现有证据的基础上提供实用的评估。
■最新的ASM有可能有效治疗儿童局灶性发作性癫痫，治疗选择应考虑几个药物和癫痫相关因素。未来的治疗应该越来越个性化，并针对患者特定的途径。未来的研究不仅应该专注于发现新的化合物，而且应该专注于重新利用用于其他适应症的药物。
